Persistent or recurrent bronchogenic carcinoma: Detection with PET and 2-[F-18]-2-deoxy-D-glucose1

Edward F. Patz, Val Lowe, John M. Hoffman, Susan S. Paine, Laura K. Harris, Philip C. Goodman

Research output: Contribution to journalArticle

192 Citations (Scopus)

Abstract

PURPOSE: To assess positron emission tomography (PET) with 2-[fluorine-18]-2-deoxy-D-glucose (FDG) in the differentiation of recurrent bronchogenic carcinoma from fibrosis after therapy. MATERIALS AND METHODS: Any patient treated for bronchogenic carcinoma who had a residual chest radiographic abnormality was eligible. Forty-three patients (mean age, 63.5 years) participated. Chest radiographs and thoracic computed tomographic scans helped localize the abnormality prior to PET. Semiquantitative analysis was performed on FDG PET images with calculated standardized uptake ratios (SURs). Sensitivity, specificity, and confidence intervals for recurrent disease were determined. RESULTS: Thirty-five patients had recurrent or persistent tumor (median SUR, 7.6; range, 1.9-18.7). Eight patients had fibrosis but no evidence of disease (SUR, 1.6; range, 0.6-2.4). The sensitivity for detecting recurrent tumor (SUR > 2.5) was 97.1%, and specificity was 100%. The SUR for recurrent tumor was statistically significantly higher than for fibrosis (P = .0001). CONCLUSION: FDG PET accurately helps differentiate recurrent bronchogenic carcinoma from fibrosis.

Original languageEnglish (US)
Pages (from-to)379-382
Number of pages4
JournalRadiology
Volume191
Issue number2
StatePublished - May 1994
Externally publishedYes

Fingerprint

Bronchogenic Carcinoma
Positron-Emission Tomography
Fibrosis
Thorax
Neoplasms
Fluorine
Deoxyglucose
Confidence Intervals
Sensitivity and Specificity
Therapeutics

Keywords

  • Lung neoplasms, diagnosis, 60.32
  • Lung neoplasms, emission CT (ECT), 60.12163
  • Lung, fibrosis, 60.47

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Patz, E. F., Lowe, V., Hoffman, J. M., Paine, S. S., Harris, L. K., & Goodman, P. C. (1994). Persistent or recurrent bronchogenic carcinoma: Detection with PET and 2-[F-18]-2-deoxy-D-glucose1. Radiology, 191(2), 379-382.

Persistent or recurrent bronchogenic carcinoma : Detection with PET and 2-[F-18]-2-deoxy-D-glucose1. / Patz, Edward F.; Lowe, Val; Hoffman, John M.; Paine, Susan S.; Harris, Laura K.; Goodman, Philip C.

In: Radiology, Vol. 191, No. 2, 05.1994, p. 379-382.

Research output: Contribution to journalArticle

Patz, EF, Lowe, V, Hoffman, JM, Paine, SS, Harris, LK & Goodman, PC 1994, 'Persistent or recurrent bronchogenic carcinoma: Detection with PET and 2-[F-18]-2-deoxy-D-glucose1', Radiology, vol. 191, no. 2, pp. 379-382.
Patz EF, Lowe V, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent bronchogenic carcinoma: Detection with PET and 2-[F-18]-2-deoxy-D-glucose1. Radiology. 1994 May;191(2):379-382.
Patz, Edward F. ; Lowe, Val ; Hoffman, John M. ; Paine, Susan S. ; Harris, Laura K. ; Goodman, Philip C. / Persistent or recurrent bronchogenic carcinoma : Detection with PET and 2-[F-18]-2-deoxy-D-glucose1. In: Radiology. 1994 ; Vol. 191, No. 2. pp. 379-382.
@article{45f95471d73843c7bb63233af592e631,
title = "Persistent or recurrent bronchogenic carcinoma: Detection with PET and 2-[F-18]-2-deoxy-D-glucose1",
abstract = "PURPOSE: To assess positron emission tomography (PET) with 2-[fluorine-18]-2-deoxy-D-glucose (FDG) in the differentiation of recurrent bronchogenic carcinoma from fibrosis after therapy. MATERIALS AND METHODS: Any patient treated for bronchogenic carcinoma who had a residual chest radiographic abnormality was eligible. Forty-three patients (mean age, 63.5 years) participated. Chest radiographs and thoracic computed tomographic scans helped localize the abnormality prior to PET. Semiquantitative analysis was performed on FDG PET images with calculated standardized uptake ratios (SURs). Sensitivity, specificity, and confidence intervals for recurrent disease were determined. RESULTS: Thirty-five patients had recurrent or persistent tumor (median SUR, 7.6; range, 1.9-18.7). Eight patients had fibrosis but no evidence of disease (SUR, 1.6; range, 0.6-2.4). The sensitivity for detecting recurrent tumor (SUR > 2.5) was 97.1{\%}, and specificity was 100{\%}. The SUR for recurrent tumor was statistically significantly higher than for fibrosis (P = .0001). CONCLUSION: FDG PET accurately helps differentiate recurrent bronchogenic carcinoma from fibrosis.",
keywords = "Lung neoplasms, diagnosis, 60.32, Lung neoplasms, emission CT (ECT), 60.12163, Lung, fibrosis, 60.47",
author = "Patz, {Edward F.} and Val Lowe and Hoffman, {John M.} and Paine, {Susan S.} and Harris, {Laura K.} and Goodman, {Philip C.}",
year = "1994",
month = "5",
language = "English (US)",
volume = "191",
pages = "379--382",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "2",

}

TY - JOUR

T1 - Persistent or recurrent bronchogenic carcinoma

T2 - Detection with PET and 2-[F-18]-2-deoxy-D-glucose1

AU - Patz, Edward F.

AU - Lowe, Val

AU - Hoffman, John M.

AU - Paine, Susan S.

AU - Harris, Laura K.

AU - Goodman, Philip C.

PY - 1994/5

Y1 - 1994/5

N2 - PURPOSE: To assess positron emission tomography (PET) with 2-[fluorine-18]-2-deoxy-D-glucose (FDG) in the differentiation of recurrent bronchogenic carcinoma from fibrosis after therapy. MATERIALS AND METHODS: Any patient treated for bronchogenic carcinoma who had a residual chest radiographic abnormality was eligible. Forty-three patients (mean age, 63.5 years) participated. Chest radiographs and thoracic computed tomographic scans helped localize the abnormality prior to PET. Semiquantitative analysis was performed on FDG PET images with calculated standardized uptake ratios (SURs). Sensitivity, specificity, and confidence intervals for recurrent disease were determined. RESULTS: Thirty-five patients had recurrent or persistent tumor (median SUR, 7.6; range, 1.9-18.7). Eight patients had fibrosis but no evidence of disease (SUR, 1.6; range, 0.6-2.4). The sensitivity for detecting recurrent tumor (SUR > 2.5) was 97.1%, and specificity was 100%. The SUR for recurrent tumor was statistically significantly higher than for fibrosis (P = .0001). CONCLUSION: FDG PET accurately helps differentiate recurrent bronchogenic carcinoma from fibrosis.

AB - PURPOSE: To assess positron emission tomography (PET) with 2-[fluorine-18]-2-deoxy-D-glucose (FDG) in the differentiation of recurrent bronchogenic carcinoma from fibrosis after therapy. MATERIALS AND METHODS: Any patient treated for bronchogenic carcinoma who had a residual chest radiographic abnormality was eligible. Forty-three patients (mean age, 63.5 years) participated. Chest radiographs and thoracic computed tomographic scans helped localize the abnormality prior to PET. Semiquantitative analysis was performed on FDG PET images with calculated standardized uptake ratios (SURs). Sensitivity, specificity, and confidence intervals for recurrent disease were determined. RESULTS: Thirty-five patients had recurrent or persistent tumor (median SUR, 7.6; range, 1.9-18.7). Eight patients had fibrosis but no evidence of disease (SUR, 1.6; range, 0.6-2.4). The sensitivity for detecting recurrent tumor (SUR > 2.5) was 97.1%, and specificity was 100%. The SUR for recurrent tumor was statistically significantly higher than for fibrosis (P = .0001). CONCLUSION: FDG PET accurately helps differentiate recurrent bronchogenic carcinoma from fibrosis.

KW - Lung neoplasms, diagnosis, 60.32

KW - Lung neoplasms, emission CT (ECT), 60.12163

KW - Lung, fibrosis, 60.47

UR - http://www.scopus.com/inward/record.url?scp=0028325906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028325906&partnerID=8YFLogxK

M3 - Article

C2 - 8153309

AN - SCOPUS:0028325906

VL - 191

SP - 379

EP - 382

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 2

ER -